The abstract is read at the publisher; the summary is JClub's.
Fractionated-dose 225Ac-J591 in metastatic, androgen pathway modulation-resistant prostate cancer shows an RP2D of 60 KBq/kg twice, with DLTs guiding tolerability.
- Why it matters: The study addresses the need to establish safe dosing for PSMA-targeted alpha therapy in patients whose disease has progressed despite androgen pathway modulation.
- What they did: In a Phase I parallel dose-escalation/expansion design, patients received either fractionated dosing (45–65 KBq/kg on days 1 and 15) or multiple cycles (45–65 KBq/kg every 6 weeks up to 4), with DLT and RP2D as primary endpoints.
- The result: DLTs occurred in 3 fractionated-dose patients, supporting RP2D 60 KBq/kg twice, while 7 DLTs in the multiple-cycle regimen led to not recommending further development; PSA declines >50% occurred in 60% (and 28% with multiple cycles).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.